Status | Study |
Terminated |
Study Name: Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1. Condition: Neurofibromatosis Type 1 Date: 2014-02-26 |
Recruiting |
Study Name: A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Condition: Pilomyxoid Astrocytoma Pilocytic Astrocytoma Glioma, Astro Date: 2013-04-16 Interventions: Drug: Mebendazole Mebendazole |
Active, not recruiting |
Study Name: PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) Condition: Neurofibromatosis-1 Optic Glioma Plexiform Neurofibroma Date: 2013-02-25 |
Active, not recruiting |
Study Name: Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Condition: Neurofibromatosis Type 1 Recurrent Childhood Pilocytic Astrocytoma Date: 2012-03-10 Interventions: Drug: Lenalidomide Given PO |
Terminated |
Study Name: Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas Condition: neurofibromatosis1 (NF1) Recurrent or Progressive Optic Pathway Gliomas (OPG) Date: 2011-04-18 Interventions: Drug: Sorafenib (Nexavar) Sorafenib (in tablet form) will |
Withdrawn |
Study Name: Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma Condition: Optic Nerve Glioma Date: 2010-12-13 Interventions: Drug: Temozolomide Study subje |
Recruiting |
Study Name: Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Condition: Glioma Neurofibromatosis Type 1 Recurrent Childhood Pilocy Date: 2010-03-17 Interventions: Other: Laboratory Biomarker Analysis |
Terminated |
Study Name: Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Condition: Childhood Atypical Teratoid/Rhabdoid Tumor Childhood Central Nervous System Choriocarcinoma Date: 2010-03-16 Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097 |
Completed |
Study Name: Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Condition: Childhood Atypical Teratoid/Rhabdoid Tumor Childhood Central Nervous System Choriocarcinoma Date: 2010-02-25 Interventions: Drug: vorinostat Other Names: |
Completed |
Study Name: Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Condition: Childhood Burkitt Lymphoma Childhood Central Nervous System Choriocarcinoma Date: 2009-10-10 Interventions: Drug: vorinostat Given orally |